Advertisement
JNJ vs NVS
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- Different scale and structure: JNJ is a diversified healthcare conglomerate spanning pharmaceuticals and medical devices, while NVS is a more focused, pure-play branded pharmaceuticals company.
- Contrasting momentum: Johnson & Johnson has delivered stronger year-to-date and 12-month price performance, while Novartis shares have been more volatile recently due to clinical pipeline readouts.
- Different catalysts: JNJ is leaning on new drug launches to offset the loss of exclusivity on Stelara, whereas NVS is managing generic erosion of Entresto while pushing newer growth brands.
- Pipeline risk profile: Novartis has experienced several late-stage trial setbacks in recent months, while Johnson & Johnson's near-term narrative has centered more on commercial execution and MedTech.
- Valuation gap: NVS trades at a lower forward earnings multiple and a higher dividend yield than JNJ, reflecting differing growth expectations and pipeline uncertainty.
- For deeper detail, explore JNJ Major News and JNJ Today's Price Move, as well as NVS Major News and NVS Today's Price Move.
- To see how AI-driven systems are positioning across both tickers, explore the Trending AI Robots.
Introduction
Johnson & Johnson (JNJ) and Novartis AG (NVS) are two of the world's largest pharmaceutical franchises, yet they represent very different investment profiles. One is a diversified healthcare giant combining medicines and medical technology; the other is a focused innovator navigating a wave of patent expirations. This comparison is most relevant for investors weighing stability against pipeline-driven upside, and for traders tracking how sentiment shifts around earnings, drug approvals, and clinical trial results. Understanding their relative performance, risk factors, and market positioning can help clarify where each name fits within a healthcare allocation.
JNJ Overview and Recent Performance
Johnson & Johnson is a diversified healthcare company whose operations span Innovative Medicine (pharmaceuticals) and MedTech (medical devices and technologies). Recent weeks have brought mixed signals. The company's latest quarterly results showed adjusted earnings that exceeded expectations but sales that fell short, with strong growth in Innovative Medicine partly offset by a softer MedTech segment. Investor focus has centered on how new products, including recently launched therapies across oncology, immunology, and neuroscience, are offsetting the loss of exclusivity (the end of patent protection) on the blockbuster drug Stelara.
From a price perspective, JNJ has been a relative outperformer over the trailing 12 months, and the stock recently reclaimed its 50-day simple moving average (a technical indicator tracking the average closing price over 50 sessions), signaling improving near-term momentum. The stock carries a higher price-to-earnings ratio than its peer, reflecting confidence in its diversified model, though near-term earnings have declined year over year.
NVS Overview and Recent Performance
Novartis AG is a Swiss-based, pure-play innovative medicines company focused on oncology, immunology, cardiovascular, and neuroscience therapies. Its recent story has been defined by a transition period: the heart-failure drug Entresto, its longtime top seller, is losing roughly half its sales to generics in the United States, while newer growth brands such as Kisqali, Scemblix, Pluvicto, and Leqvio are accelerating at high double-digit rates.
Recent market activity around NVS has been more volatile than for JNJ, driven largely by clinical pipeline news. Two late-stage trials failed to meet their primary goals in recent months, pressuring the shares, while a third candidate in multiple sclerosis met its endpoints but delivered results investors viewed as weaker than a competitor's. These binary clinical outcomes have made the stock sensitive to laboratory results as much as quarterly financials. Despite this, Novartis has maintained its long-term sales growth target and trades at a lower forward earnings multiple with a higher dividend yield than Johnson & Johnson.
Trending AI Robots
For traders who prefer a data-driven approach to navigating names like these, Tickeron's Trending AI Robots page offers a curated view of its best-performing AI trading bots. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only those most suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance metrics, and the specific sets of tickers they monitor, giving traders the flexibility to match a system to their own objectives. Exploring the page can help you identify which automated strategies are currently demonstrating the strongest momentum and alignment with prevailing conditions.
Head-to-Head Comparison
The core trade-off between these two names is diversification versus focus. JNJ offers a broader revenue base that includes a sizable MedTech business, which can cushion volatility in any single therapeutic area but also dilutes the impact of high-growth drug franchises. NVS is more concentrated, meaning its newer oncology and immunology drugs can move results more directly, but generic erosion and clinical setbacks land harder on the share price.
On growth drivers, both companies are replacing legacy blockbusters, but the paths differ. Johnson & Johnson is managing Stelara's patent expiry through a wave of new launches and a stated ambition to grow oncology sales significantly by 2030. Novartis is confronting a steeper near-term Entresto decline while leaning on five fast-growing franchises. On risk, NVS carries higher binary pipeline risk, given recent trial failures, while JNJ's risk is more spread across commercial execution and device-market dynamics. In terms of market sentiment, JNJ has shown greater trend consistency and stability, whereas NVS has displayed sharper swings tied to news flow. Finally, valuation favors NVS on a multiple and yield basis, but that discount reflects its pipeline uncertainty.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI-driven analysis would likely favor JNJ in the current environment. Johnson & Johnson has demonstrated steadier upward momentum, a more diversified earnings base, and recently reclaimed a key technical level, while Novartis remains subject to elevated volatility from clinical readouts and generic erosion. That said, NVS offers a more attractive valuation and yield, which could appeal to a different risk profile. The probabilistic edge currently tilts toward JNJ for trend-following and stability-oriented strategies, while NVS may present opportunities for traders comfortable with catalyst-driven price swings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and NVS is a Hold.
JNJ in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.360). P/E Ratio (31.640) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
NVS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.360). P/E Ratio (24.370) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
JNJ | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 2 | 4 | |
SMR RATING 1..100 | 37 | 33 | |
PRICE GROWTH RATING 1..100 | 18 | 40 | |
P/E GROWTH RATING 1..100 | 6 | 13 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (54) in the Pharmaceuticals Major industry is in the same range as JNJ (75). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (4). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
NVS's SMR Rating (33) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that NVS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (18) in the Pharmaceuticals Major industry is in the same range as NVS (40). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
JNJ's P/E Growth Rating (6) in the Pharmaceuticals Major industry is in the same range as NVS (13). This means that JNJ’s stock grew similarly to NVS’s over the last 12 months.
| JNJ | NVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 59% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 38% |
| Momentum ODDS (%) | 1 day ago 45% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 40% | N/A |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 50% | 1 day ago 51% |
| Advances ODDS (%) | 10 days ago 46% | 12 days ago 55% |
| Declines ODDS (%) | 5 days ago 43% | N/A |
| BollingerBands ODDS (%) | 1 day ago 41% | 1 day ago 30% |
| Aroon ODDS (%) | 1 day ago 44% | 1 day ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).
- JNJ’s TA Score: 6 bullish, 4 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +1.11% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
JNJ is expected to report earnings on Jan 26, 2027.
NVS is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.